Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,24561338,flow rate,"Chromatographic separation of analytes was performed on YMC pack ODS AM (150mm×4.6mm, 5μm) column under gradient conditions with acetonitrile:2.0mM ammonium acetate buffer as the mobile phase at a flow rate of 1ml/min.",Simultaneous quantification of ruxolitinib and nilotinib in rat plasma by LC-MS/MS: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24561338/),[ml] / [min],1,3650,DB04868,Nilotinib
,24561338,extraction recovery,"Mean extraction recovery for ruxolitinib, nilotinib, and IS of 99.6%, 97.6% and 90.3% were consistent across low, medium, and high QC levels.",Simultaneous quantification of ruxolitinib and nilotinib in rat plasma by LC-MS/MS: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24561338/),%,99.6,3651,DB04868,Nilotinib
,24561338,extraction recovery,"Mean extraction recovery for ruxolitinib, nilotinib, and IS of 99.6%, 97.6% and 90.3% were consistent across low, medium, and high QC levels.",Simultaneous quantification of ruxolitinib and nilotinib in rat plasma by LC-MS/MS: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24561338/),%,97.6,3652,DB04868,Nilotinib
,24561338,extraction recovery,"Mean extraction recovery for ruxolitinib, nilotinib, and IS of 99.6%, 97.6% and 90.3% were consistent across low, medium, and high QC levels.",Simultaneous quantification of ruxolitinib and nilotinib in rat plasma by LC-MS/MS: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24561338/),%,90.3,3653,DB04868,Nilotinib
,20520639,times,"Median times from diagnosis of CP or AP to nilotinib therapy were 89 and 83 months, respectively.",Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20520639/),month,89,12771,DB04868,Nilotinib
,20520639,times,"Median times from diagnosis of CP or AP to nilotinib therapy were 89 and 83 months, respectively.",Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20520639/),month,83,12772,DB04868,Nilotinib
,21827214,Absolute bioavailability,Absolute bioavailability in humans has been investigated only for imatinib (almost 100%) and pazopanib (14-39%; n = 3).,"Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),%,100,12901,DB04868,Nilotinib
,21827214,Absolute bioavailability,Absolute bioavailability in humans has been investigated only for imatinib (almost 100%) and pazopanib (14-39%; n = 3).,"Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),%,14-39,12902,DB04868,Nilotinib
,21827214,absolute bioavailability,"Quite low absolute bioavailability under fasted conditions is assumed for nilotinib (31%), sorafenib (50%) and sunitinib (50%).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),%,31,12903,DB04868,Nilotinib
,21827214,absolute bioavailability,"Quite low absolute bioavailability under fasted conditions is assumed for nilotinib (31%), sorafenib (50%) and sunitinib (50%).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),%,50,12904,DB04868,Nilotinib
,21827214,accumulation ratios,"At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),,1.5-2.5,12905,DB04868,Nilotinib
,21827214,accumulation ratios,"At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),,2.0,12906,DB04868,Nilotinib
,21827214,accumulation ratios,"At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),,3,12907,DB04868,Nilotinib
,21827214,accumulation ratios,"At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),,1.2-4.5,12908,DB04868,Nilotinib
,21827214,accumulation ratios,"At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),,5.7-6.4,12909,DB04868,Nilotinib
,21827214,accumulation ratios,"At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),,3.0-4.5,12910,DB04868,Nilotinib
,21419933,elimination half-life,"These studies show that the maximum plasma concentration of nilotinib is reached 3 to 4 hours after oral administration, with an elimination half-life of 17 hours through metabolism via oxidation and hydroxylation.",Pharmacokinetics and pharmacodynamics of nilotinib in gastrointestinal stromal tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21419933/),h,17,13128,DB04868,Nilotinib
,20498287,t(max),"Nilotinib t(max) was prolonged from 4.0 to 6.0 hours, but t(1/2) was not altered.",Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498287/),h,4.0 to 6.0,16195,DB04868,Nilotinib
,20498287,gastric pH,"Mean gastric pH was 1.0 +/- 0.5 at baseline and increased to 2.79 +/- 2.50, 3.98 +/- 2.27, 5.30 +/- 1.70, 5.38 +/- 1.26, and 5.31 +/- 1.42 at predose and 1, 2, 3, and 4 hours after the fifth esomeprazole dose, respectively.",Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498287/),,1.0,16196,DB04868,Nilotinib
,20498287,gastric pH,"Mean gastric pH was 1.0 +/- 0.5 at baseline and increased to 2.79 +/- 2.50, 3.98 +/- 2.27, 5.30 +/- 1.70, 5.38 +/- 1.26, and 5.31 +/- 1.42 at predose and 1, 2, 3, and 4 hours after the fifth esomeprazole dose, respectively.",Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498287/),,2.79,16197,DB04868,Nilotinib
,20498287,gastric pH,"Mean gastric pH was 1.0 +/- 0.5 at baseline and increased to 2.79 +/- 2.50, 3.98 +/- 2.27, 5.30 +/- 1.70, 5.38 +/- 1.26, and 5.31 +/- 1.42 at predose and 1, 2, 3, and 4 hours after the fifth esomeprazole dose, respectively.",Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498287/),,3.98,16198,DB04868,Nilotinib
,20498287,gastric pH,"Mean gastric pH was 1.0 +/- 0.5 at baseline and increased to 2.79 +/- 2.50, 3.98 +/- 2.27, 5.30 +/- 1.70, 5.38 +/- 1.26, and 5.31 +/- 1.42 at predose and 1, 2, 3, and 4 hours after the fifth esomeprazole dose, respectively.",Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498287/),,5.30,16199,DB04868,Nilotinib
,20498287,gastric pH,"Mean gastric pH was 1.0 +/- 0.5 at baseline and increased to 2.79 +/- 2.50, 3.98 +/- 2.27, 5.30 +/- 1.70, 5.38 +/- 1.26, and 5.31 +/- 1.42 at predose and 1, 2, 3, and 4 hours after the fifth esomeprazole dose, respectively.",Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498287/),,5.38,16200,DB04868,Nilotinib
,20498287,gastric pH,"Mean gastric pH was 1.0 +/- 0.5 at baseline and increased to 2.79 +/- 2.50, 3.98 +/- 2.27, 5.30 +/- 1.70, 5.38 +/- 1.26, and 5.31 +/- 1.42 at predose and 1, 2, 3, and 4 hours after the fifth esomeprazole dose, respectively.",Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498287/),,5.31,16201,DB04868,Nilotinib
,25540064,PFS,PFS and OS rates at week 96 were 21 and 43 %.,A phase 1/2 study of bosutinib in Japanese adults with Philadelphia chromosome-positive chronic myeloid leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25540064/),%,21,36679,DB04868,Nilotinib
,25540064,OS rates,PFS and OS rates at week 96 were 21 and 43 %.,A phase 1/2 study of bosutinib in Japanese adults with Philadelphia chromosome-positive chronic myeloid leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25540064/),%,43,36680,DB04868,Nilotinib
,32152879,plasma concentrations,"The plasma concentrations of dasatinib before, immediately, and 2 h after the completion of hemodialysis were 7.4, 6.1, and 59.5 ng/mL, respectively.",Pharmacokinetics of dasatinib in a hemodialysis patient with chronic myeloid leukemia and chronic kidney disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32152879/),,6.1,39573,DB04868,Nilotinib
,32152879,plasma concentrations,"The plasma concentrations of dasatinib before, immediately, and 2 h after the completion of hemodialysis were 7.4, 6.1, and 59.5 ng/mL, respectively.",Pharmacokinetics of dasatinib in a hemodialysis patient with chronic myeloid leukemia and chronic kidney disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32152879/),,59.5,39574,DB04868,Nilotinib
,32152879,trough concentration,"Because the patient's dasatinib trough concentration was higher (6.1 ng/mL) than the target level (1.5 ng/mL), we suspected the development of dasatinib-related heart dysfunction; thus, dasatinib was discontinued 6 months after its initiation.",Pharmacokinetics of dasatinib in a hemodialysis patient with chronic myeloid leukemia and chronic kidney disease. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32152879/),[ng] / [ml],6.1,39575,DB04868,Nilotinib
,32152879,trough concentration,"Because the patient's dasatinib trough concentration was higher (6.1 ng/mL) than the target level (1.5 ng/mL), we suspected the development of dasatinib-related heart dysfunction; thus, dasatinib was discontinued 6 months after its initiation.",Pharmacokinetics of dasatinib in a hemodialysis patient with chronic myeloid leukemia and chronic kidney disease. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32152879/),[ng] / [ml],1.5,39576,DB04868,Nilotinib
,34406581,trough,"Notably, serial evaluation of the PK of ponatinib showed that the median trough values (ng/ml) were 17.2 (12.2-34.5), 33.1 (21.2-40.3) and 27.7 (13.6-29.9) in patients 1, 2, and 3, respectively.",Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph + ALL. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34406581/),[ng] / [ml],17.2,50813,DB04868,Nilotinib
,34406581,trough,"Notably, serial evaluation of the PK of ponatinib showed that the median trough values (ng/ml) were 17.2 (12.2-34.5), 33.1 (21.2-40.3) and 27.7 (13.6-29.9) in patients 1, 2, and 3, respectively.",Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph + ALL. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34406581/),[ng] / [ml],33.1,50814,DB04868,Nilotinib
,34406581,trough,"Notably, serial evaluation of the PK of ponatinib showed that the median trough values (ng/ml) were 17.2 (12.2-34.5), 33.1 (21.2-40.3) and 27.7 (13.6-29.9) in patients 1, 2, and 3, respectively.",Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph + ALL. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34406581/),[ng] / [ml],27.7,50815,DB04868,Nilotinib
,22080802,flow rate,Chromatographic separation of the drugs is achieved on an RP-C(18) column at flow rate of 0.9 mL/min at 35°C; eluate is monitored at 267 nm.,A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22080802/),[ml] / [min],0.9,53637,DB04868,Nilotinib
,22080802,extraction recovery,Mean intra-day and inter-day precision for all compounds are 2.5 and 13.3%; mean accuracy is 13.9%; extraction recovery ranges within 40.24 and 81.81%.,A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22080802/),%,40.24,53638,DB04868,Nilotinib
,22080802,extraction recovery,Mean intra-day and inter-day precision for all compounds are 2.5 and 13.3%; mean accuracy is 13.9%; extraction recovery ranges within 40.24 and 81.81%.,A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22080802/),%,81.81,53639,DB04868,Nilotinib
,22080802,Limits of detection,"Limits of detection are 10 ng/mL for imatinib and nilotinib, 50 ng/mL for dasatinib; limits of quantitation are 50 ng/mL for imatinib and nilotinib, 100 ng/mL for dasatinib.",A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22080802/),[ng] / [ml],10,53640,DB04868,Nilotinib
,22080802,Limits of detection,"Limits of detection are 10 ng/mL for imatinib and nilotinib, 50 ng/mL for dasatinib; limits of quantitation are 50 ng/mL for imatinib and nilotinib, 100 ng/mL for dasatinib.",A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22080802/),[ng] / [ml],50,53641,DB04868,Nilotinib
,22080802,limits of quantitation,"Limits of detection are 10 ng/mL for imatinib and nilotinib, 50 ng/mL for dasatinib; limits of quantitation are 50 ng/mL for imatinib and nilotinib, 100 ng/mL for dasatinib.",A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22080802/),[ng] / [ml],50,53642,DB04868,Nilotinib
,22080802,limits of quantitation,"Limits of detection are 10 ng/mL for imatinib and nilotinib, 50 ng/mL for dasatinib; limits of quantitation are 50 ng/mL for imatinib and nilotinib, 100 ng/mL for dasatinib.",A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22080802/),[ng] / [ml],100,53643,DB04868,Nilotinib
,24643910,MM constant (Km),"The MM constant (Km) values of OATP-1B1 for nilotinib and vandetanib are 10.14±1.91 and 2.72±0.25 μM, respectively, and Vmax values of OATP-1B1 for nilotinib and vandetanib were 6.95±0.47 and 75.95±1.99 nmol/mg protein per minute, respectively.",Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24643910/),μM,10.14,58786,DB04868,Nilotinib
,24643910,MM constant (Km),"The MM constant (Km) values of OATP-1B1 for nilotinib and vandetanib are 10.14±1.91 and 2.72±0.25 μM, respectively, and Vmax values of OATP-1B1 for nilotinib and vandetanib were 6.95±0.47 and 75.95±1.99 nmol/mg protein per minute, respectively.",Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24643910/),μM,2.72,58787,DB04868,Nilotinib
,24643910,Vmax,"The MM constant (Km) values of OATP-1B1 for nilotinib and vandetanib are 10.14±1.91 and 2.72±0.25 μM, respectively, and Vmax values of OATP-1B1 for nilotinib and vandetanib were 6.95±0.47 and 75.95±1.99 nmol/mg protein per minute, respectively.",Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24643910/),[nM] / [·mg·min],6.95,58788,DB04868,Nilotinib
,24643910,Vmax,"The MM constant (Km) values of OATP-1B1 for nilotinib and vandetanib are 10.14±1.91 and 2.72±0.25 μM, respectively, and Vmax values of OATP-1B1 for nilotinib and vandetanib were 6.95±0.47 and 75.95±1.99 nmol/mg protein per minute, respectively.",Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24643910/),[nM] / [·mg·min],75.95,58789,DB04868,Nilotinib
,24643910,Km,"Likewise, Km values of OATP-1B3 for canertinib, nilotinib and vandetanib were 12.18±3.32, 7.84±1.43 and 4.37±0.79 μM, respectively, and Vmax values of OATP-1B3 for canertinib, nilotinib and vandetanib were 15.34±1.59, 6.75±0.42 and 194.64±10.58 nmol/mg protein per minute, respectively.",Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24643910/),μM,12.18,58790,DB04868,Nilotinib
,24643910,Km,"Likewise, Km values of OATP-1B3 for canertinib, nilotinib and vandetanib were 12.18±3.32, 7.84±1.43 and 4.37±0.79 μM, respectively, and Vmax values of OATP-1B3 for canertinib, nilotinib and vandetanib were 15.34±1.59, 6.75±0.42 and 194.64±10.58 nmol/mg protein per minute, respectively.",Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24643910/),μM,7.84,58791,DB04868,Nilotinib
,24643910,Km,"Likewise, Km values of OATP-1B3 for canertinib, nilotinib and vandetanib were 12.18±3.32, 7.84±1.43 and 4.37±0.79 μM, respectively, and Vmax values of OATP-1B3 for canertinib, nilotinib and vandetanib were 15.34±1.59, 6.75±0.42 and 194.64±10.58 nmol/mg protein per minute, respectively.",Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24643910/),μM,4.37,58792,DB04868,Nilotinib
,24643910,Vmax,"Likewise, Km values of OATP-1B3 for canertinib, nilotinib and vandetanib were 12.18±3.32, 7.84±1.43 and 4.37±0.79 μM, respectively, and Vmax values of OATP-1B3 for canertinib, nilotinib and vandetanib were 15.34±1.59, 6.75±0.42 and 194.64±10.58 nmol/mg protein per minute, respectively.",Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24643910/),[nM] / [·mg·min],15.34,58793,DB04868,Nilotinib
,24643910,Vmax,"Likewise, Km values of OATP-1B3 for canertinib, nilotinib and vandetanib were 12.18±3.32, 7.84±1.43 and 4.37±0.79 μM, respectively, and Vmax values of OATP-1B3 for canertinib, nilotinib and vandetanib were 15.34±1.59, 6.75±0.42 and 194.64±10.58 nmol/mg protein per minute, respectively.",Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24643910/),[nM] / [·mg·min],6.75,58794,DB04868,Nilotinib
,24643910,Vmax,"Likewise, Km values of OATP-1B3 for canertinib, nilotinib and vandetanib were 12.18±3.32, 7.84±1.43 and 4.37±0.79 μM, respectively, and Vmax values of OATP-1B3 for canertinib, nilotinib and vandetanib were 15.34±1.59, 6.75±0.42 and 194.64±10.58 nmol/mg protein per minute, respectively.",Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24643910/),[nM] / [·mg·min],194.64,58795,DB04868,Nilotinib
,21184622,C(max),"Mean ± SD serum nilotinib C(max) was 1872 ± 560 ng/mL, which is comparable to steady-state C(max) in CML and gastrointestinal stromal tumour patients receiving twice-daily 400 mg doses.","Effects of nilotinib on single-dose warfarin pharmacokinetics and pharmacodynamics: a randomized, single-blind, two-period crossover study in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21184622/),[ng] / [ml],1872,92199,DB04868,Nilotinib
,33315105,Cerebrospinal fluid/serum ratio,Cerebrospinal fluid/serum ratio of nilotinib concentration was 0.2% to 0.3%.,Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33315105/),,0.2,95017,DB04868,Nilotinib
,33315105,Cerebrospinal fluid/serum ratio,Cerebrospinal fluid/serum ratio of nilotinib concentration was 0.2% to 0.3%.,Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33315105/),%,0.3,95018,DB04868,Nilotinib
,20110053,t(1/2),"The mean (SD) t(1/2) was 15.1 (4.97) and 16.0 (9.13) hours in the mild-impairment and control groups, respectively, but was 21.6 (7.77) and 32.4 (10.7) hours in the moderate- and severe-impairment groups, respectively, reflecting the decrease in CL/F and/or increase in Vz/F in the latter 2 groups.","Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110053/),h,15.1,95914,DB04868,Nilotinib
,20110053,t(1/2),"The mean (SD) t(1/2) was 15.1 (4.97) and 16.0 (9.13) hours in the mild-impairment and control groups, respectively, but was 21.6 (7.77) and 32.4 (10.7) hours in the moderate- and severe-impairment groups, respectively, reflecting the decrease in CL/F and/or increase in Vz/F in the latter 2 groups.","Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110053/),h,16.0,95915,DB04868,Nilotinib
,20110053,t(1/2),"The mean (SD) t(1/2) was 15.1 (4.97) and 16.0 (9.13) hours in the mild-impairment and control groups, respectively, but was 21.6 (7.77) and 32.4 (10.7) hours in the moderate- and severe-impairment groups, respectively, reflecting the decrease in CL/F and/or increase in Vz/F in the latter 2 groups.","Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110053/),h,21.6,95916,DB04868,Nilotinib
,20110053,t(1/2),"The mean (SD) t(1/2) was 15.1 (4.97) and 16.0 (9.13) hours in the mild-impairment and control groups, respectively, but was 21.6 (7.77) and 32.4 (10.7) hours in the moderate- and severe-impairment groups, respectively, reflecting the decrease in CL/F and/or increase in Vz/F in the latter 2 groups.","Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110053/),h,32.4,95917,DB04868,Nilotinib
,32764164,C m i n ∞ $,"The mean imatinib and nilotinib C m i n ∞ ${C}_{min}\hat{\infty }$ were 1,065.46 ± 765.71 and 1,445 ± 1,010.35 ng/mL respectively.",Relationship between trough level of tyrosine kinase inhibitor (imatinib and nilotinib) and BCR-ABL ratios in an Indonesian chronic-phase chronic myeloid leukemia (CML) population. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32764164/),[ng] / [ml],"1,065.46",109669,DB04868,Nilotinib
,32764164,C m i n ∞ $,"The mean imatinib and nilotinib C m i n ∞ ${C}_{min}\hat{\infty }$ were 1,065.46 ± 765.71 and 1,445 ± 1,010.35 ng/mL respectively.",Relationship between trough level of tyrosine kinase inhibitor (imatinib and nilotinib) and BCR-ABL ratios in an Indonesian chronic-phase chronic myeloid leukemia (CML) population. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32764164/),[ng] / [ml],"1,445",109670,DB04868,Nilotinib
≥,32764164,C m i n ∞ $,"Half of the patients in each group were found to reach C m i n ∞ ${C}_{min}\hat{\infty }$ target (≥1.000 ng/mL, imatinib; ≥800 ng/mL nilotinib), but only 12 (35,29%) of them result in BCR-ABL ratio ≤0.1%.",Relationship between trough level of tyrosine kinase inhibitor (imatinib and nilotinib) and BCR-ABL ratios in an Indonesian chronic-phase chronic myeloid leukemia (CML) population. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32764164/),[ng] / [ml],1.000,109671,DB04868,Nilotinib
≥,32764164,C m i n ∞ $,"Half of the patients in each group were found to reach C m i n ∞ ${C}_{min}\hat{\infty }$ target (≥1.000 ng/mL, imatinib; ≥800 ng/mL nilotinib), but only 12 (35,29%) of them result in BCR-ABL ratio ≤0.1%.",Relationship between trough level of tyrosine kinase inhibitor (imatinib and nilotinib) and BCR-ABL ratios in an Indonesian chronic-phase chronic myeloid leukemia (CML) population. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32764164/),[ng] / [m],800,109672,DB04868,Nilotinib
,30919310,plasma:brain ratio,"Our results indicate that the effective dose of Nilotinib has the lowest plasma:brain ratio (1%) followed by Bosutinib and Radotinib (5%), Bafetinib (12%) and LCB-03-0110 (12%).",Multikinase Abl/DDR/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in Neurodegeneration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30919310/),%,1,115901,DB04868,Nilotinib
,30919310,plasma:brain ratio,"Our results indicate that the effective dose of Nilotinib has the lowest plasma:brain ratio (1%) followed by Bosutinib and Radotinib (5%), Bafetinib (12%) and LCB-03-0110 (12%).",Multikinase Abl/DDR/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in Neurodegeneration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30919310/),%,5,115902,DB04868,Nilotinib
,30919310,plasma:brain ratio,"Our results indicate that the effective dose of Nilotinib has the lowest plasma:brain ratio (1%) followed by Bosutinib and Radotinib (5%), Bafetinib (12%) and LCB-03-0110 (12%).",Multikinase Abl/DDR/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in Neurodegeneration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30919310/),%,12,115903,DB04868,Nilotinib
,27995880,Cmax,"The major pharmacokinetic parameters were as follows: Cmax (209.01±58.69) μg/L and (223.07±79.51) μg/L, Tmax (1.1±0.8) h and (1.1±0.8) h, T1/2 (5.10±1.34) h and (4.39±0.74) h, AUC0-τ (646.65±185.67) h·μg/L and (695.84±273.40) h·μg/L (all P>0.05); AUC0-∝ (668.11±186.00) h·μg/L and (712.42±278.08) h·μg/L, MRT (5.32 ± 1.70) h and (4.68 ± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),[μg] / [l],209.01,121364,DB04868,Nilotinib
,27995880,Cmax,"The major pharmacokinetic parameters were as follows: Cmax (209.01±58.69) μg/L and (223.07±79.51) μg/L, Tmax (1.1±0.8) h and (1.1±0.8) h, T1/2 (5.10±1.34) h and (4.39±0.74) h, AUC0-τ (646.65±185.67) h·μg/L and (695.84±273.40) h·μg/L (all P>0.05); AUC0-∝ (668.11±186.00) h·μg/L and (712.42±278.08) h·μg/L, MRT (5.32 ± 1.70) h and (4.68 ± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),[μg] / [l],223.07,121365,DB04868,Nilotinib
,27995880,Tmax,"The major pharmacokinetic parameters were as follows: Cmax (209.01±58.69) μg/L and (223.07±79.51) μg/L, Tmax (1.1±0.8) h and (1.1±0.8) h, T1/2 (5.10±1.34) h and (4.39±0.74) h, AUC0-τ (646.65±185.67) h·μg/L and (695.84±273.40) h·μg/L (all P>0.05); AUC0-∝ (668.11±186.00) h·μg/L and (712.42±278.08) h·μg/L, MRT (5.32 ± 1.70) h and (4.68 ± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),h,1.1,121366,DB04868,Nilotinib
,27995880,T1/2,"The major pharmacokinetic parameters were as follows: Cmax (209.01±58.69) μg/L and (223.07±79.51) μg/L, Tmax (1.1±0.8) h and (1.1±0.8) h, T1/2 (5.10±1.34) h and (4.39±0.74) h, AUC0-τ (646.65±185.67) h·μg/L and (695.84±273.40) h·μg/L (all P>0.05); AUC0-∝ (668.11±186.00) h·μg/L and (712.42±278.08) h·μg/L, MRT (5.32 ± 1.70) h and (4.68 ± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),h,5.10,121367,DB04868,Nilotinib
,27995880,T1/2,"The major pharmacokinetic parameters were as follows: Cmax (209.01±58.69) μg/L and (223.07±79.51) μg/L, Tmax (1.1±0.8) h and (1.1±0.8) h, T1/2 (5.10±1.34) h and (4.39±0.74) h, AUC0-τ (646.65±185.67) h·μg/L and (695.84±273.40) h·μg/L (all P>0.05); AUC0-∝ (668.11±186.00) h·μg/L and (712.42±278.08) h·μg/L, MRT (5.32 ± 1.70) h and (4.68 ± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),h,4.39,121368,DB04868,Nilotinib
,27995880,AUC0-τ,"The major pharmacokinetic parameters were as follows: Cmax (209.01±58.69) μg/L and (223.07±79.51) μg/L, Tmax (1.1±0.8) h and (1.1±0.8) h, T1/2 (5.10±1.34) h and (4.39±0.74) h, AUC0-τ (646.65±185.67) h·μg/L and (695.84±273.40) h·μg/L (all P>0.05); AUC0-∝ (668.11±186.00) h·μg/L and (712.42±278.08) h·μg/L, MRT (5.32 ± 1.70) h and (4.68 ± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),[h·μg] / [l],646.65,121369,DB04868,Nilotinib
,27995880,AUC0-τ,"The major pharmacokinetic parameters were as follows: Cmax (209.01±58.69) μg/L and (223.07±79.51) μg/L, Tmax (1.1±0.8) h and (1.1±0.8) h, T1/2 (5.10±1.34) h and (4.39±0.74) h, AUC0-τ (646.65±185.67) h·μg/L and (695.84±273.40) h·μg/L (all P>0.05); AUC0-∝ (668.11±186.00) h·μg/L and (712.42±278.08) h·μg/L, MRT (5.32 ± 1.70) h and (4.68 ± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),[h·μg] / [l],695.84,121370,DB04868,Nilotinib
,27995880,AUC0-∝,"The major pharmacokinetic parameters were as follows: Cmax (209.01±58.69) μg/L and (223.07±79.51) μg/L, Tmax (1.1±0.8) h and (1.1±0.8) h, T1/2 (5.10±1.34) h and (4.39±0.74) h, AUC0-τ (646.65±185.67) h·μg/L and (695.84±273.40) h·μg/L (all P>0.05); AUC0-∝ (668.11±186.00) h·μg/L and (712.42±278.08) h·μg/L, MRT (5.32 ± 1.70) h and (4.68 ± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),[h·μg] / [l],668.11,121371,DB04868,Nilotinib
,27995880,AUC0-∝,"The major pharmacokinetic parameters were as follows: Cmax (209.01±58.69) μg/L and (223.07±79.51) μg/L, Tmax (1.1±0.8) h and (1.1±0.8) h, T1/2 (5.10±1.34) h and (4.39±0.74) h, AUC0-τ (646.65±185.67) h·μg/L and (695.84±273.40) h·μg/L (all P>0.05); AUC0-∝ (668.11±186.00) h·μg/L and (712.42±278.08) h·μg/L, MRT (5.32 ± 1.70) h and (4.68 ± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),[h·μg] / [l],712.42,121372,DB04868,Nilotinib
,27995880,MRT,"The major pharmacokinetic parameters were as follows: Cmax (209.01±58.69) μg/L and (223.07±79.51) μg/L, Tmax (1.1±0.8) h and (1.1±0.8) h, T1/2 (5.10±1.34) h and (4.39±0.74) h, AUC0-τ (646.65±185.67) h·μg/L and (695.84±273.40) h·μg/L (all P>0.05); AUC0-∝ (668.11±186.00) h·μg/L and (712.42±278.08) h·μg/L, MRT (5.32 ± 1.70) h and (4.68 ± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),h,5.32,121373,DB04868,Nilotinib
,27995880,MRT,"The major pharmacokinetic parameters were as follows: Cmax (209.01±58.69) μg/L and (223.07±79.51) μg/L, Tmax (1.1±0.8) h and (1.1±0.8) h, T1/2 (5.10±1.34) h and (4.39±0.74) h, AUC0-τ (646.65±185.67) h·μg/L and (695.84±273.40) h·μg/L (all P>0.05); AUC0-∝ (668.11±186.00) h·μg/L and (712.42±278.08) h·μg/L, MRT (5.32 ± 1.70) h and (4.68 ± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),h,4.68,121374,DB04868,Nilotinib
,23097199,CL/Q(H),"The systemic clearance (CL) of nilotinib was relatively low in rodents with a value of less than 25% of hepatic blood flow (Q(H)), while it was moderate in monkeys and dogs (CL/Q(H) = 32-35%).",Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic availability. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23097199/),%,32-35,129819,DB04868,Nilotinib
,23097199,steady state volume of distribution (V(ss) ),The steady state volume of distribution (V(ss) ) ranged from 0.55 to 3.9 l/kg across the species tested.,Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic availability. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23097199/),[l] / [kg],0.55 to 3.9,129820,DB04868,Nilotinib
,23097199,bioavailability,The maximum concentration (C(max)) of nilotinib occurred at 0.5-4 h and the bioavailability was moderate (17-44%).,Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic availability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23097199/),%,17-44,129821,DB04868,Nilotinib
>,23097199,plasma protein binding,The plasma protein binding was high (> 97.5%) in preclinical species and humans.,Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic availability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23097199/),%,97.5,129822,DB04868,Nilotinib
,23097199,CL,"The human CL (~ 0.1 l/h/kg) and V(ss) (~2.0 l/kg) were best predicted by the rat-dog-human proportionality method and allometric scaling method, respectively.",Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic availability. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23097199/),[l] / [h·kg],0.1,129823,DB04868,Nilotinib
,23097199,V(ss),"The human CL (~ 0.1 l/h/kg) and V(ss) (~2.0 l/kg) were best predicted by the rat-dog-human proportionality method and allometric scaling method, respectively.",Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic availability. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23097199/),[l] / [kg],2.0,129824,DB04868,Nilotinib
<,23097199,absolute oral bioavailability,The absolute oral bioavailability of nilotinib in healthy humans was predicted to be low (< 25%).,Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic availability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23097199/),%,25,129825,DB04868,Nilotinib
,31163185,EC50,"Nilotinib was a potent inhibitor of Pgp, Bcrp1, and BCRP, with EC50 values of 2.22, 2.47, and 0.692 μM, respectively.",Nilotinib Alters the Efflux Transporter-Mediated Pharmacokinetics of Afatinib in Mice. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31163185/),μM,2.22,133087,DB04868,Nilotinib
,31163185,EC50,"Nilotinib was a potent inhibitor of Pgp, Bcrp1, and BCRP, with EC50 values of 2.22, 2.47, and 0.692 μM, respectively.",Nilotinib Alters the Efflux Transporter-Mediated Pharmacokinetics of Afatinib in Mice. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31163185/),μM,2.47,133088,DB04868,Nilotinib
,31163185,EC50,"Nilotinib was a potent inhibitor of Pgp, Bcrp1, and BCRP, with EC50 values of 2.22, 2.47, and 0.692 μM, respectively.",Nilotinib Alters the Efflux Transporter-Mediated Pharmacokinetics of Afatinib in Mice. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31163185/),μM,0.692,133089,DB04868,Nilotinib
,31163185,clearance,"Nilotinib also decreased the clearance of afatinib by 65.3%, from 609 to 211 mL/h.",Nilotinib Alters the Efflux Transporter-Mediated Pharmacokinetics of Afatinib in Mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31163185/),[ml] / [h],609,133090,DB04868,Nilotinib
,31163185,clearance,"Nilotinib also decreased the clearance of afatinib by 65.3%, from 609 to 211 mL/h.",Nilotinib Alters the Efflux Transporter-Mediated Pharmacokinetics of Afatinib in Mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31163185/),[ml] / [h],211,133091,DB04868,Nilotinib
,30514402,elimination half-lives,"In general, elimination half-lives of these agents in mice and guinea pigs were much shorter (1-3 h) relative to those in larger species such as prairie dogs and monkeys.",Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30514402/),h,1-3,134334,DB04868,Nilotinib
,30514402,elimination half-life,"The longer nilotinib elimination half-life in prairie dogs (i.v., 6.5 h and oral, 7.5 h), facilitated multiple dosing PK and safety assessment.",Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30514402/),h,6.5,134335,DB04868,Nilotinib
,30514402,elimination half-life,"The longer nilotinib elimination half-life in prairie dogs (i.v., 6.5 h and oral, 7.5 h), facilitated multiple dosing PK and safety assessment.",Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30514402/),h,7.5,134336,DB04868,Nilotinib
,19695406,T(max),Median T(max) was ~2 hours after administration of single and multiple doses.,"Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695406/),h,2,139225,DB04868,Nilotinib
,19695406,C(min),"At steady state, C(min) was 1025.4 ng/mL and C(max) was 2160.7 ng/mL.","Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695406/),[ng] / [ml],1025.4,139226,DB04868,Nilotinib
,19695406,C(max),"At steady state, C(min) was 1025.4 ng/mL and C(max) was 2160.7 ng/mL.","Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695406/),[ng] / [ml],2160.7,139227,DB04868,Nilotinib
,19695406,AUCs from time 0 to the end of the dosing interval tau (AUC(0-tau)),"Mean AUCs from time 0 to the end of the dosing interval tau (AUC(0-tau)) were 5076.3 and 17,751.3 ng .","Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695406/),ng,5076.3,139228,DB04868,Nilotinib
,19695406,AUCs from time 0 to the end of the dosing interval tau (AUC(0-tau)),"Mean AUCs from time 0 to the end of the dosing interval tau (AUC(0-tau)) were 5076.3 and 17,751.3 ng .","Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695406/),ng,"17,751.3",139229,DB04868,Nilotinib
,19695406,accumulation factor,"h/mL at days 1 and 15, respectively, representing an accumulation factor of 3.92.","Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695406/),,3.92,139230,DB04868,Nilotinib
,19695406,Apparent oral clearance (CL/F),"Apparent oral clearance (CL/F) was 0.39 L/h/kg (range, 0.12-0.74 L/h/ kg) at steady state.","Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695406/),[l] / [h·kg],0.39,139231,DB04868,Nilotinib
,32332918,plasma concentrations of NIL (C-NIL),Mean and median plasma concentrations of NIL (C-NIL) were 817 (SD ± 450) and 773 ng/ml.,"Nilotinib in steroid-refractory cGVHD: prospective parallel evaluation of response, according to NIH criteria and exploratory response criteria (GITMO criteria). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32332918/),[ng] / [ml],817,154291,DB04868,Nilotinib
,32332918,plasma concentrations of NIL (C-NIL),Mean and median plasma concentrations of NIL (C-NIL) were 817 (SD ± 450) and 773 ng/ml.,"Nilotinib in steroid-refractory cGVHD: prospective parallel evaluation of response, according to NIH criteria and exploratory response criteria (GITMO criteria). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32332918/),[ng] / [ml],773,154292,DB04868,Nilotinib
,17291840,total run time,The total run time is 25 min.,"High-performance liquid chromatography method with ultraviolet detection for the quantification of the BCR-ABL inhibitor nilotinib (AMN107) in plasma, urine, culture medium and cell preparations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17291840/),min,25,165198,DB04868,Nilotinib
,17291840,Limit of detection,Limit of detection was 0.002 microg/ml in plasma and 0.01 microg/ml in urine.,"High-performance liquid chromatography method with ultraviolet detection for the quantification of the BCR-ABL inhibitor nilotinib (AMN107) in plasma, urine, culture medium and cell preparations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17291840/),[μg] / [ml],0.002,165199,DB04868,Nilotinib
,17291840,Limit of detection,Limit of detection was 0.002 microg/ml in plasma and 0.01 microg/ml in urine.,"High-performance liquid chromatography method with ultraviolet detection for the quantification of the BCR-ABL inhibitor nilotinib (AMN107) in plasma, urine, culture medium and cell preparations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17291840/),[μg] / [ml],0.01,165200,DB04868,Nilotinib
,20957481,progression-free survival (PFS),"Median progression-free survival (PFS) and overall survival (OS) were 23.6 weeks (95% confidence interval [CI] 0.0-50.6 weeks) and 74.0 weeks (95% CI 27.4-120.6 weeks), respectively.",Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20957481/),weeks,23.6,186383,DB04868,Nilotinib
,20957481,overall survival (OS),"Median progression-free survival (PFS) and overall survival (OS) were 23.6 weeks (95% confidence interval [CI] 0.0-50.6 weeks) and 74.0 weeks (95% CI 27.4-120.6 weeks), respectively.",Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20957481/),weeks,74.0,186384,DB04868,Nilotinib
,20957481,C (max),"Pharmacokinetic parameters of nilotinib were as follows: C (max) of 1,754 ± 970 μg/L, T(1/2) of 13.4 ± 8.94 h and AUC (0-12 h) of 14,190 ± 6,853 h μg/L.",Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20957481/),[μg] / [l],"1,754",186385,DB04868,Nilotinib
,20957481,T(1/2),"Pharmacokinetic parameters of nilotinib were as follows: C (max) of 1,754 ± 970 μg/L, T(1/2) of 13.4 ± 8.94 h and AUC (0-12 h) of 14,190 ± 6,853 h μg/L.",Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20957481/),h,13.4,186386,DB04868,Nilotinib
,20957481,AUC (0-12 h),"Pharmacokinetic parameters of nilotinib were as follows: C (max) of 1,754 ± 970 μg/L, T(1/2) of 13.4 ± 8.94 h and AUC (0-12 h) of 14,190 ± 6,853 h μg/L.",Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20957481/),[h·μg] / [l],"14,190",186387,DB04868,Nilotinib
,20957481,AUC (0-12 h),"The AUC (0-12 h) of nilotinib was significantly lower in the 4 patients with prior major (total or subtotal) gastrectomy than in the other 13 patients (8,526 ± 7,869 h μg/L vs. 15,930 ± 5,759 h μg/L, P = 0.014).",Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20957481/),[h·μg] / [l],"8,526",186388,DB04868,Nilotinib
,20957481,AUC (0-12 h),"The AUC (0-12 h) of nilotinib was significantly lower in the 4 patients with prior major (total or subtotal) gastrectomy than in the other 13 patients (8,526 ± 7,869 h μg/L vs. 15,930 ± 5,759 h μg/L, P = 0.014).",Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20957481/),[h·μg] / [l],"15,930",186389,DB04868,Nilotinib
,20957481,AUC (0-12 h),"Of the 4 gastrectomized patients, two (50%) showed markedly decreased nilotinib exposure (AUC (0-12 h) of 1,914 and 3,194 h μg/L) and rapid disease progression (PFS of 4.6 and 7.1 weeks).",Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20957481/),[h·μg] / [l],"1,914",186390,DB04868,Nilotinib
,20957481,AUC (0-12 h),"Of the 4 gastrectomized patients, two (50%) showed markedly decreased nilotinib exposure (AUC (0-12 h) of 1,914 and 3,194 h μg/L) and rapid disease progression (PFS of 4.6 and 7.1 weeks).",Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20957481/),[h·μg] / [l],"3,194",186391,DB04868,Nilotinib
,25102852,"AUC24,ss","The geometric mean of sunitinib and SU12662 AUC24,ss was decreased by 21% and 28% in patients with both gastrectomy and small bowel resection (n = 8) compared to controls (n = 63) for sunitinib (931 ng hr/mL (95%-CI; 676-1283) versus 1177 ng hr/mL (95%-CI; 1097-1263); p < 0.05) and SU12662 (354 ng hr/mL (95%-CI; 174-720) versus 492 ng hr/mL (95%-CI; 435-555); p < 0.05).",Effect of gastrointestinal resection on sunitinib exposure in patients with GIST. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25102852/),[h·ng] / [ml],931,188378,DB04868,Nilotinib
,25102852,"AUC24,ss","The geometric mean of sunitinib and SU12662 AUC24,ss was decreased by 21% and 28% in patients with both gastrectomy and small bowel resection (n = 8) compared to controls (n = 63) for sunitinib (931 ng hr/mL (95%-CI; 676-1283) versus 1177 ng hr/mL (95%-CI; 1097-1263); p < 0.05) and SU12662 (354 ng hr/mL (95%-CI; 174-720) versus 492 ng hr/mL (95%-CI; 435-555); p < 0.05).",Effect of gastrointestinal resection on sunitinib exposure in patients with GIST. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25102852/),[h·ng] / [ml],1177,188379,DB04868,Nilotinib
,25102852,"AUC24,ss","The geometric mean of sunitinib and SU12662 AUC24,ss was decreased by 21% and 28% in patients with both gastrectomy and small bowel resection (n = 8) compared to controls (n = 63) for sunitinib (931 ng hr/mL (95%-CI; 676-1283) versus 1177 ng hr/mL (95%-CI; 1097-1263); p < 0.05) and SU12662 (354 ng hr/mL (95%-CI; 174-720) versus 492 ng hr/mL (95%-CI; 435-555); p < 0.05).",Effect of gastrointestinal resection on sunitinib exposure in patients with GIST. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25102852/),[h·ng] / [ml],354,188380,DB04868,Nilotinib
,25102852,"AUC24,ss","The geometric mean of sunitinib and SU12662 AUC24,ss was decreased by 21% and 28% in patients with both gastrectomy and small bowel resection (n = 8) compared to controls (n = 63) for sunitinib (931 ng hr/mL (95%-CI; 676-1283) versus 1177 ng hr/mL (95%-CI; 1097-1263); p < 0.05) and SU12662 (354 ng hr/mL (95%-CI; 174-720) versus 492 ng hr/mL (95%-CI; 435-555); p < 0.05).",Effect of gastrointestinal resection on sunitinib exposure in patients with GIST. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25102852/),[h·ng] / [ml],492,188381,DB04868,Nilotinib
,26195136,IC50,"One of the most potent compounds 4e strongly suppresses Bcr-Abl(WT) and Bcr-Abl(T315I) kinase with IC50 values of 5.0 and 9.0 nM, and inhibits the proliferation of K562 and murine Ba/F3 cells ectopically expressing Bcr-Abl(T315I) cells with IC50 values of 2 and 50 nM, respectively.",Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl(T315I) mutant. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26195136/),nM,5.0,190770,DB04868,Nilotinib
,26195136,IC50,"One of the most potent compounds 4e strongly suppresses Bcr-Abl(WT) and Bcr-Abl(T315I) kinase with IC50 values of 5.0 and 9.0 nM, and inhibits the proliferation of K562 and murine Ba/F3 cells ectopically expressing Bcr-Abl(T315I) cells with IC50 values of 2 and 50 nM, respectively.",Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl(T315I) mutant. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26195136/),nM,9.0,190771,DB04868,Nilotinib
,26195136,IC50,"One of the most potent compounds 4e strongly suppresses Bcr-Abl(WT) and Bcr-Abl(T315I) kinase with IC50 values of 5.0 and 9.0 nM, and inhibits the proliferation of K562 and murine Ba/F3 cells ectopically expressing Bcr-Abl(T315I) cells with IC50 values of 2 and 50 nM, respectively.",Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl(T315I) mutant. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26195136/),nM,2,190772,DB04868,Nilotinib
,26195136,IC50,"One of the most potent compounds 4e strongly suppresses Bcr-Abl(WT) and Bcr-Abl(T315I) kinase with IC50 values of 5.0 and 9.0 nM, and inhibits the proliferation of K562 and murine Ba/F3 cells ectopically expressing Bcr-Abl(T315I) cells with IC50 values of 2 and 50 nM, respectively.",Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl(T315I) mutant. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26195136/),nM,50,190773,DB04868,Nilotinib
,26195136,oral bioavailability,"It also displays good pharmacokinetics properties with an oral bioavailability of 35.3% and T(1/2) value of 48.7 h, and demonstrates significantly suppression on tumor growth in xenografted mice of K562 and Ba/F3 cells expressing Bcr-Abl(T315I).",Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl(T315I) mutant. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26195136/),%,35.3,190774,DB04868,Nilotinib
,26195136,T(1/2),"It also displays good pharmacokinetics properties with an oral bioavailability of 35.3% and T(1/2) value of 48.7 h, and demonstrates significantly suppression on tumor growth in xenografted mice of K562 and Ba/F3 cells expressing Bcr-Abl(T315I).",Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl(T315I) mutant. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26195136/),h,48.7,190775,DB04868,Nilotinib
,31676669,area under the concentration-time curve at steady state,"The area under the concentration-time curve at steady state was slightly lower in pediatric patients versus adults (14,751.4 vs. 17,102.9 ng/h/mL); the geometric mean ratio (GMR; pediatric:adult) was 0.86 [90% confidence interval (CI), 0.70-1.06].",Pharmacokinetics of Nilotinib in Pediatric Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia or Acute Lymphoblastic Leukemia. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31676669/),[ng] / [h·ml],"14,751.4",221031,DB04868,Nilotinib
,31676669,area under the concentration-time curve at steady state,"The area under the concentration-time curve at steady state was slightly lower in pediatric patients versus adults (14,751.4 vs. 17,102.9 ng/h/mL); the geometric mean ratio (GMR; pediatric:adult) was 0.86 [90% confidence interval (CI), 0.70-1.06].",Pharmacokinetics of Nilotinib in Pediatric Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia or Acute Lymphoblastic Leukemia. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31676669/),[ng] / [h·ml],"17,102.9",221032,DB04868,Nilotinib
,32243653,Cmin,"Nilotinib PK following 200 mg BID taken with a meal strongly resembled that of 300 mg BID taken fasted (Cmin percentile (P)10-P90: 665-1404 ng/mL and 557-1743 ng/mL, respectively).",Food-effect study of nilotinib in chronic myeloid leukaemia (NiFo study): Enabling dose reduction and relief of treatment burden. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32243653/),[ng] / [ml],665-1404,242673,DB04868,Nilotinib
,32243653,Cmin,"Nilotinib PK following 200 mg BID taken with a meal strongly resembled that of 300 mg BID taken fasted (Cmin percentile (P)10-P90: 665-1404 ng/mL and 557-1743 ng/mL, respectively).",Food-effect study of nilotinib in chronic myeloid leukaemia (NiFo study): Enabling dose reduction and relief of treatment burden. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32243653/),[ng] / [ml],557-1743,242674,DB04868,Nilotinib
,24036846,area under the plasma concentration versus time curve,"Calcium supplementation did not significantly affect nilotinib pharmacokinetic parameters including area under the plasma concentration versus time curve (18.4 μg/mL h alone vs. 16.9 μg/mL h with calcium carbonate, p = 0.83; 80 % power); maximum plasma concentration (C(max)) (0.670 μg/mL alone vs. 6.18 μg/mL with calcium carbonate, p = 0.97); or half-life (18.9 h alone vs. 17.2 h with calcium carbonate, p = 0.18).",Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24036846/),[μg] / [h·ml],18.4,251791,DB04868,Nilotinib
,24036846,area under the plasma concentration versus time curve,"Calcium supplementation did not significantly affect nilotinib pharmacokinetic parameters including area under the plasma concentration versus time curve (18.4 μg/mL h alone vs. 16.9 μg/mL h with calcium carbonate, p = 0.83; 80 % power); maximum plasma concentration (C(max)) (0.670 μg/mL alone vs. 6.18 μg/mL with calcium carbonate, p = 0.97); or half-life (18.9 h alone vs. 17.2 h with calcium carbonate, p = 0.18).",Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24036846/),[μg] / [h·ml],16.9,251792,DB04868,Nilotinib
,24036846,maximum plasma concentration (C(max)),"Calcium supplementation did not significantly affect nilotinib pharmacokinetic parameters including area under the plasma concentration versus time curve (18.4 μg/mL h alone vs. 16.9 μg/mL h with calcium carbonate, p = 0.83; 80 % power); maximum plasma concentration (C(max)) (0.670 μg/mL alone vs. 6.18 μg/mL with calcium carbonate, p = 0.97); or half-life (18.9 h alone vs. 17.2 h with calcium carbonate, p = 0.18).",Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24036846/),[μg] / [ml],0.670,251793,DB04868,Nilotinib
,24036846,maximum plasma concentration (C(max)),"Calcium supplementation did not significantly affect nilotinib pharmacokinetic parameters including area under the plasma concentration versus time curve (18.4 μg/mL h alone vs. 16.9 μg/mL h with calcium carbonate, p = 0.83; 80 % power); maximum plasma concentration (C(max)) (0.670 μg/mL alone vs. 6.18 μg/mL with calcium carbonate, p = 0.97); or half-life (18.9 h alone vs. 17.2 h with calcium carbonate, p = 0.18).",Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24036846/),[μg] / [ml],6.18,251794,DB04868,Nilotinib
,24036846,half-life,"Calcium supplementation did not significantly affect nilotinib pharmacokinetic parameters including area under the plasma concentration versus time curve (18.4 μg/mL h alone vs. 16.9 μg/mL h with calcium carbonate, p = 0.83; 80 % power); maximum plasma concentration (C(max)) (0.670 μg/mL alone vs. 6.18 μg/mL with calcium carbonate, p = 0.97); or half-life (18.9 h alone vs. 17.2 h with calcium carbonate, p = 0.18).",Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24036846/),h,18.9,251795,DB04868,Nilotinib
,24036846,half-life,"Calcium supplementation did not significantly affect nilotinib pharmacokinetic parameters including area under the plasma concentration versus time curve (18.4 μg/mL h alone vs. 16.9 μg/mL h with calcium carbonate, p = 0.83; 80 % power); maximum plasma concentration (C(max)) (0.670 μg/mL alone vs. 6.18 μg/mL with calcium carbonate, p = 0.97); or half-life (18.9 h alone vs. 17.2 h with calcium carbonate, p = 0.18).",Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24036846/),h,17.2,251796,DB04868,Nilotinib
,29404062,flow rate,The flow rate was 0.25 mL/min and the total run time was 6 min.,"A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404062/),[ml] / [min],0.25,256216,DB04868,Nilotinib
,29404062,total run time,The flow rate was 0.25 mL/min and the total run time was 6 min.,"A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404062/),min,6,256217,DB04868,Nilotinib
,29404062,m/,"The multiple reaction monitoring (MRM) transitions, m/z 494.5→394.5 for imatinib, 488.7→401.5 for dasatinib, 530.7→289.5 for nilotinib and 528.5→403.4 for IS, were chosen to achieve high selectivity in the simultaneous analyses.","A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404062/),,494.5,256218,DB04868,Nilotinib
,29404062,m/,"The multiple reaction monitoring (MRM) transitions, m/z 494.5→394.5 for imatinib, 488.7→401.5 for dasatinib, 530.7→289.5 for nilotinib and 528.5→403.4 for IS, were chosen to achieve high selectivity in the simultaneous analyses.","A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404062/),,394.5,256219,DB04868,Nilotinib
,29404062,m/,"The multiple reaction monitoring (MRM) transitions, m/z 494.5→394.5 for imatinib, 488.7→401.5 for dasatinib, 530.7→289.5 for nilotinib and 528.5→403.4 for IS, were chosen to achieve high selectivity in the simultaneous analyses.","A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404062/),,488.7,256220,DB04868,Nilotinib
,29404062,m/,"The multiple reaction monitoring (MRM) transitions, m/z 494.5→394.5 for imatinib, 488.7→401.5 for dasatinib, 530.7→289.5 for nilotinib and 528.5→403.4 for IS, were chosen to achieve high selectivity in the simultaneous analyses.","A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404062/),,530.7,256221,DB04868,Nilotinib
,29404062,m/,"The multiple reaction monitoring (MRM) transitions, m/z 494.5→394.5 for imatinib, 488.7→401.5 for dasatinib, 530.7→289.5 for nilotinib and 528.5→403.4 for IS, were chosen to achieve high selectivity in the simultaneous analyses.","A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404062/),,289.5,256222,DB04868,Nilotinib
,29404062,m/,"The multiple reaction monitoring (MRM) transitions, m/z 494.5→394.5 for imatinib, 488.7→401.5 for dasatinib, 530.7→289.5 for nilotinib and 528.5→403.4 for IS, were chosen to achieve high selectivity in the simultaneous analyses.","A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404062/),,528.5,256223,DB04868,Nilotinib
,25418605,AUC(inf),"In the repeated-dose study, the values for AUC(inf) and C(max) were 2.6 (90%CI, 2.1-3.3) and 2.0 (90%CI, 1.7-2.4), respectively.",Inhibitory effect of single and repeated doses of nilotinib on the pharmacokinetics of CYP3A substrate midazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25418605/),,2.6,261284,DB04868,Nilotinib
,25418605,C(max),"In the repeated-dose study, the values for AUC(inf) and C(max) were 2.6 (90%CI, 2.1-3.3) and 2.0 (90%CI, 1.7-2.4), respectively.",Inhibitory effect of single and repeated doses of nilotinib on the pharmacokinetics of CYP3A substrate midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25418605/),,2.0,261285,DB04868,Nilotinib
,19723647,CL/F,"Oral clearance (CL/F) of nilotinib was similar across the combination groups (mean CL/F, 19.1-25.6 L/h), and lower than in the single-agent cohort (mean CL/F, 35.6 L/h).",A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19723647/),[l] / [h],19.1-25.6,266108,DB04868,Nilotinib
,19723647,CL/F,"Oral clearance (CL/F) of nilotinib was similar across the combination groups (mean CL/F, 19.1-25.6 L/h), and lower than in the single-agent cohort (mean CL/F, 35.6 L/h).",A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19723647/),[l] / [h],35.6,266109,DB04868,Nilotinib
,19723647,progression-free survival,Thirty-eight patients had stable disease and two patients achieved partial response with a median progression-free survival of 134 days for the entire group.,A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19723647/),d,134,266110,DB04868,Nilotinib
,28703026,fetal/maternal,The fetal/maternal concentration ratio ranged from 0.5 to 0.58 for nilotinib and from 0.05 to 0.22 for imatinib.,Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28703026/),,0.5 to 0.58,272680,DB04868,Nilotinib
,28703026,concentration ratio,The fetal/maternal concentration ratio ranged from 0.5 to 0.58 for nilotinib and from 0.05 to 0.22 for imatinib.,Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28703026/),,0.5 to 0.58,272681,DB04868,Nilotinib
,28703026,concentration ratio,The fetal/maternal concentration ratio ranged from 0.5 to 0.58 for nilotinib and from 0.05 to 0.22 for imatinib.,Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28703026/),,0.05 to 0.22,272682,DB04868,Nilotinib
